178 related articles for article (PubMed ID: 31640083)
1. Circulating lncRNA H19 may be a useful marker of response to neoadjuvant chemotherapy in breast cancer.
Özgür E; Ferhatoğlu F; Şen F; Saip P; Gezer U
Cancer Biomark; 2020; 27(1):11-17. PubMed ID: 31640083
[TBL] [Abstract][Full Text] [Related]
2. Circulating lncRNA H19 in plasma as a novel biomarker for breast cancer.
Zhang K; Luo Z; Zhang Y; Zhang L; Wu L; Liu L; Yang J; Song X; Liu J
Cancer Biomark; 2016 Jun; 17(2):187-94. PubMed ID: 27540977
[TBL] [Abstract][Full Text] [Related]
3. Circulating long noncoding RNA GAS5 as a potential biomarker in breast cancer for assessing the surgical effects.
Han L; Ma P; Liu SM; Zhou X
Tumour Biol; 2016 May; 37(5):6847-54. PubMed ID: 26662314
[TBL] [Abstract][Full Text] [Related]
4. Interplay of lncRNA H19/miR-675 and lncRNA NEAT1/miR-204 in breast cancer.
Müller V; Oliveira-Ferrer L; Steinbach B; Pantel K; Schwarzenbach H
Mol Oncol; 2019 May; 13(5):1137-1149. PubMed ID: 30803129
[TBL] [Abstract][Full Text] [Related]
5. Circulating HOTAIR expression predicts the clinical response to neoadjuvant chemotherapy in patients with breast cancer.
Lu R; Zhang J; Zhang W; Huang Y; Wang N; Zhang Q; Qu S
Cancer Biomark; 2018; 22(2):249-256. PubMed ID: 29630518
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy.
Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
J BUON; 2013; 18(2):366-71. PubMed ID: 23818347
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo studies on the association of long non‑coding RNAs H19 and urothelial cancer associated 1 with the susceptibility to 5‑fluorouracil in rectal cancer.
Yokoyama Y; Sakatani T; Wada R; Ishino K; Kudo M; Koizumi M; Yamada T; Yoshida H; Naito Z
Int J Oncol; 2019 Dec; 55(6):1361-1371. PubMed ID: 31638183
[TBL] [Abstract][Full Text] [Related]
9. A Minimal lncRNA-mRNA Signature Predicts Sensitivity to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Wang Q; Li C; Tang P; Ji R; Chen S; Wen J
Cell Physiol Biochem; 2018; 48(6):2539-2548. PubMed ID: 30121642
[TBL] [Abstract][Full Text] [Related]
10. LncRNA BCAR4 expression predicts the clinical response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Gan FJ; Li Y; Xu MX; Zhou T; Wu S; Hu K; Li Y; Sun SH; Luo Q
Cancer Biomark; 2021; 32(3):339-351. PubMed ID: 34151842
[TBL] [Abstract][Full Text] [Related]
11. Clinical Significance of Long Non-coding RNA MALAT1 Expression in Tissue and Serum of Breast Cancer.
Miao Y; Fan R; Chen L; Qian H
Ann Clin Lab Sci; 2016 Jul; 46(4):418-24. PubMed ID: 27466303
[TBL] [Abstract][Full Text] [Related]
12. Association of LncRNA MEG3 polymorphisms with efficacy of neoadjuvant chemotherapy in breast cancer.
Bayarmaa B; Wu Z; Peng J; Wang Y; Xu S; Yan T; Yin W; Lu J; Zhou L
BMC Cancer; 2019 Sep; 19(1):877. PubMed ID: 31488093
[TBL] [Abstract][Full Text] [Related]
13. Diffusion-weighted imaging in assessing pathological response of tumor in breast cancer subtype to neoadjuvant chemotherapy.
Liu S; Ren R; Chen Z; Wang Y; Fan T; Li C; Zhang P
J Magn Reson Imaging; 2015 Sep; 42(3):779-87. PubMed ID: 25580585
[TBL] [Abstract][Full Text] [Related]
14. Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer.
Sánchez-Muñoz A; Navarro-Perez V; Plata-Fernández Y; Santonja A; Moreno I; Ribelles N; Alba E
Clin Breast Cancer; 2015 Oct; 15(5):343-7. PubMed ID: 25752727
[TBL] [Abstract][Full Text] [Related]
15. Peripheral Blood Classical Monocytes and Plasma Interleukin 10 Are Associated to Neoadjuvant Chemotherapy Response in Breast Cancer Patients.
Valdés-Ferrada J; Muñoz-Durango N; Pérez-Sepulveda A; Muñiz S; Coronado-Arrázola I; Acevedo F; Soto JA; Bueno SM; Sánchez C; Kalergis AM
Front Immunol; 2020; 11():1413. PubMed ID: 32733470
[TBL] [Abstract][Full Text] [Related]
16. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.
Nahleh ZA; Barlow WE; Hayes DF; Schott AF; Gralow JR; Sikov WM; Perez EA; Chennuru S; Mirshahidi HR; Corso SW; Lew DL; Pusztai L; Livingston RB; Hortobagyi GN
Breast Cancer Res Treat; 2016 Aug; 158(3):485-95. PubMed ID: 27393622
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients.
Chen R; Ye Y; Yang C; Peng Y; Zong B; Qu F; Tang Z; Wang Y; Su X; Li H; Yang G; Liu S
Breast Cancer Res Treat; 2018 Jul; 170(1):35-43. PubMed ID: 29480449
[TBL] [Abstract][Full Text] [Related]
18. [Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer. Its relation with molecular subtypes].
Ruano R; Ramos M; García-Talavera JR; Ramos T; Rosero AS; González-Orus JM; Sancho M
Rev Esp Med Nucl Imagen Mol; 2014; 33(6):340-5. PubMed ID: 24856234
[TBL] [Abstract][Full Text] [Related]
19. A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer.
García-Vazquez R; Ruiz-García E; Meneses García A; Astudillo-de la Vega H; Lara-Medina F; Alvarado-Miranda A; Maldonado-Martínez H; González-Barrios JA; Campos-Parra AD; Rodríguez Cuevas S; Marchat LA; López-Camarillo C
Tumour Biol; 2017 Jun; 39(6):1010428317702899. PubMed ID: 28621239
[TBL] [Abstract][Full Text] [Related]
20. Circulating long noncoding RNAs H19 and GAS5 are associated with type 2 diabetes but not with diabetic retinopathy: A preliminary study.
Fawzy MS; Abdelghany AA; Toraih EA; Mohamed AM
Bosn J Basic Med Sci; 2020 Aug; 20(3):365-371. PubMed ID: 31999937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
